BioCentury | Nov 17, 2014
Company News
BHV Pharma, Libbs deal
...BHV granted Libbs exclusive rights in select Latin American countries, including Brazil, to develop and commercialize...
...Brazil, to develop and commercialize remogliflozin etabonate. BHV will receive $1.5 million up front and Libbs...
...2 (SGLT2) inhibitor in Type II diabetics, which is slated to start late this year. Libbs...
...Brazil, to develop and commercialize remogliflozin etabonate. BHV will receive $1.5 million up front and Libbs...
...2 (SGLT2) inhibitor in Type II diabetics, which is slated to start late this year. Libbs...
